Compare Moderna, Inc. (MRNA) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vistra Corp — how do they compare? Moderna, Inc. trades at $63.58 (market cap $25.42B), while Vistra Corp trades at $146.49 (market cap $49.23B). The key difference: Vistra Corp is the larger of the two by market cap, and Vistra Corp pays a 0.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VST | |
|---|---|---|
Market Cap | $25.42B | $49.23B |
Sector | Health | Technology |
52-Week High | $81.80 | $217.92 |
52-Week Low | $22.36 | $134.71 |
Enterprise Value | $21.57B | $71.17B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.65, up 5.09% on the day, with a bullish technical signal from moving averages and recent FDA approval of its mRNA flu vaccine mFLUSIVA for adults 50+. Despite negative net income margins and declining revenue since 2022, the company beat Q2 2026 EPS estimates and maintains a diversified pipeline in flu, oncology, and rare diseases. Cash flow improved in 2025 with positive net cash flow of $668 million.
The outlook hinges on pipeline execution beyond COVID-19, with growth opportunities in new vaccine approvals but significant risks from persistent losses and competitive pressures. Analyst consensus is cautious with a hold-heavy rating and $54.33 price target below the current price, indicating skepticism about near-term profitability.
Vistra Corp (VST) trades at $146.68, up 1.21% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat ($2.87 vs $1.32 expected) but missed Q4 2025 and Q2 2026 estimates, reflecting volatile performance. Fundamentals show impressive ROE of 75.73% and net income margin of 11.55%, though valuation metrics remain elevated with P/E of 24.74. Recent news highlights Vistra's positioning in the data center power boom despite ERCOT market softness.
Vistra presents a compelling growth story driven by data center electricity demand, with 91% analyst buy ratings and $239.75 price target suggesting 63% upside. However, execution risks from volatile energy markets and high valuation multiples warrant caution. The stock offers exposure to AI infrastructure growth but faces headwinds from hedging losses and competitive pressures in power markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
